Asset profile
Tafolecimab · Sintbilo
Monoclonal antibody
Evidence outlook
Approved: Primary hypercholesterolemia and mixed dyslipidemia (SINTBILO) (CN)
This approval is outside the US-scoped market view; the covered program shown here is investigational. Regulatory approval supersedes design-level evidence grading for the approved use.
track record: Reliable signal
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
79 competitors in this universe: 18 direct rivals (same mechanism and indication), 1 same-class, 60 same-indication; 18 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Tafolecimab (Sintbilo): this drug | Phase 3 | Monoclonal antibody | PCSK9 | ||
| Alirocumab (Praluent) | Approved | Monoclonal antibody | PCSK9 | ||
| Evolocumab (Repatha) | Approved | Monoclonal antibody | PCSK9 | ||
| Inclisiran (Leqvio) | Approved | RNA / oligonucleotide | PCSK9 | ||
| AZD0780 | Phase 3 | Small molecule | PCSK9 | ||
| Ebronucimab | Phase 3 | Monoclonal antibody | PCSK9 | ||
| Enlicitide | Phase 3 | Peptide | PCSK9 | ||
| Lerodalcibep (Lerochol) | Phase 3 | Protein / enzyme therapeutic | PCSK9 | ||
| Ongericimab (Junshida) | Phase 3 | Monoclonal antibody | PCSK9 | ||
| QLC7401 | Phase 3 | RNA / oligonucleotide | PCSK9 | ||
| Recaticimab | Phase 3 | Monoclonal antibody | PCSK9 | ||
| SYH2053 | Phase 3 | RNA / oligonucleotide | PCSK9 | ||
| AZD8233 | Phase 2 | RNA / oligonucleotide | PCSK9 | ||
| DNV001 | Phase 2 | Monoclonal antibody | PCSK9 | ||
| HRS-1301 | Phase 2 | Small molecule | PCSK9 | ||
| COR-1004 | Phase 1 | — | PCSK9 |
…and 64 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
12 further head-to-head pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(8 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (1)
December 2026 (1)
What to watch
2027 (5)
May 2027 (2)
August 2027 (1)
What to watch
September 2027 (1)
What to watch
November 2027 (1)
What to watch
2028 (1)
June 2028 (1)
What to watch
2030 (1)
January 2030 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.